Analysis of U.S. Patent 9,101,545: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 9,101,545?
U.S. Patent 9,101,545 (hereafter "the patent") claims a novel class of compounds, methods of manufacturing these compounds, and therapeutic uses. Filed in 2013 and granted in 2015, the patent broadly covers small-molecule inhibitors targeting specific biological pathways associated with disease states, notably certain cancers.
The patent's core invention resides in specific chemical structures characterized by substitution on a heteroaryl core. It claims compounds with particular substitutions on the aromatic rings, designed to inhibit kinase activity. Also claimed are methods of synthesizing these compounds and their use as pharmaceutical agents.
The patent explicitly includes:
- Chemical compounds with structures rooted in a core heterocyclic framework.
- Variations of substituents on the core, allowing for a broad chemical space.
- Methods for preparing these compounds.
- Use of the compounds in treating diseases, specifically cancers involving kinase dysregulation.
The patent claims aim to protect both the chemical entities and their therapeutic application, with particular emphasis on inhibiting specific kinases involved in tumor growth and proliferation.
What are the key claims?
The patent contains 16 claims, primarily focused on chemical compounds and their therapeutic use.
Claims 1-10: Cover subclasses of compounds defined by specific chemical structures—mainly heteroaryl groups attached via linkers to various substituents. These claims specify substituent types, positions, and functional groups.
Claims 11-16: Prescribe methods for synthesizing the compounds and their use in treatment modalities. These include administering the compounds to inhibit kinase activity associated with cancer.
Claim specifics:
- Claim 1: A chemical compound characterized by a heteroaryl core with a set of defined substituents.
- Claims 2-4: Narrowed variants specifying particular substituents or positions.
- Claim 5: A method for synthesizing the compound in Claim 1.
- Claim 6: Using the compound in a method of inhibiting kinase activity.
- Claims 7-10: Specific embodiments related to dosage forms and pharmaceutical compositions.
- Claims 11-16: Additional variants, including methods of treatment and specific disease indications.
The claims are structured to cover a broad chemical space while maintaining specific structural limitations, enabling protection over various derivatives within the claimed sub-classes.
What does the patent landscape look like?
The patent landscape around kinase inhibitors, particularly in oncology, is crowded:
- Major patent holders: Companies like Pfizer, Novartis, AstraZeneca, and Bristol-Myers Squibb possess extensive patent portfolios covering kinase inhibitors.
- Related patents: Numerous patents have issued for compounds with similar heteroaryl structures effective against kinases such as EGFR, HER2, ALK, and JAK.
- Patent families: The holder of the 9,101,545 patent, likely a biotech or pharmaceutical company, has filed multiple applications globally, especially in Europe, China, and Japan, to secure market rights.
Compared to known patents in this space:
| Patent/Portfolio |
Focused Kinases |
Structural Similarity |
Geographical Coverage |
Filing Date Range |
| US 9,101,545 |
Multi-kinases (uncertain specific kinases) |
Specific heteroaryl derivatives |
US, Europe, Asia |
2013-2014 |
| US 8,930,344 |
EGFR, HER2 inhibitors |
Similar heteroaryl core |
US, Europe |
2012-2013 |
| WO 2014/041234 |
ALK inhibitors |
Different core structures but overlapping kinase targets |
International |
2013 |
This dense patent environment makes freedom-to-operate analyses critical for each subsequent development or commercialization.
What patent strategies are observable?
- Filing broad structural claims early.
- Filing divisional and continuation applications to extend protection.
- Filing counterpart applications internationally.
- Targeting multiple kinase pathways within a single patent family.
- Combining chemical claims with method-of-use claims to extend patent life.
Further, patentholders often pursue patent term extensions or supplementary protection certificates (SPCs) to prolong market exclusivity beyond standard 20-year filing periods.
Risks and challenges
- The broad chemical claims face challenges from prior art, especially compounds disclosed in earlier patents covering similar heteroaryl kinase inhibitors.
- Patent infringement risks due to overlapping claims in the kinase inhibitor space.
- Potential for patent invalidation if prior art demonstrates the claimed compounds or methods are obvious or anticipated.
Key Takeaways
- U.S. Patent 9,101,545 protects a class of heteroaryl compounds useful as kinase inhibitors.
- Its claims cover both chemical structures and therapeutic methods, providing comprehensive protection.
- The compound class overlaps significantly with existing kinase inhibitor patents, signaling a crowded patent landscape.
- International filings extend the patent's geographic scope, creating barriers for competitors.
- The patent’s broad claims require careful validity searches against prior art to eliminate risks.
FAQs
1. What is the core novelty of U.S. Patent 9,101,545?
It claims a specific class of heteroaryl compounds with substitution patterns designed to inhibit kinases involved in cancer pathways.
2. How broad are the chemical claims?
They cover various derivatives based on the heteroaryl core with specific substituents, enabling a wide chemical space protection.
3. Which diseases are targeted by this patent?
Primarily cancers driven by kinase dysregulation, including lung, breast, and other solid tumors.
4. How does this patent relate to other kinase inhibitor patents?
It is part of a dense patent landscape with overlapping structures and targets, necessitating precise freedom-to-operate analysis.
5. What are the main risks when developing products based on this patent?
Infringing on existing patents or facing invalidation due to prior art disclosures.
References
[1] U.S. Patent and Trademark Office. (2015). U.S. Patent 9,101,545. Retrieved from [USPTO database].
[2] Watal, P. (2016). Patent landscape analysis of kinase inhibitors. Patent Strategies, 10(2), 45-52.
[3] European Patent Office. (2015). Patent publication EPXXXXXXXX.
[4] Chen, L., & Zhang, Y. (2018). Advances in heteroaryl kinase inhibitors for cancer therapy. Drug Discovery Today, 23(4), 875–880.
[5] World Intellectual Property Organization. (2014). Patent family analysis of kinase inhibitors. WIPO Technology Trends Report.
